量化致动脉粥样硬化脂蛋白以指导降脂策略:EAS与EFLM基于共识的推荐
欧洲动脉粥样硬化学会(EAS)与欧洲临床化学和实验室医学联盟(EFLM)联合共识小组针对致动脉粥样硬化脂蛋白的实验室诊断挑战提出推荐。总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇(LDLC)及计算的非高密度脂蛋白胆固醇(非HDLC)构成初级血脂面板,可在非空腹状态测量。LDLC是降脂治疗的主要靶标,治疗随访时应使用相同方法测量或计算以减少方法间差异导致的错误。
要点
- LDLC是降脂治疗主要靶标,随访需用相同方法测量或计算。
- 非HDLC应报告于所有标准血脂面板,并用于评估残余风险。
- 所有ASCVD风险患者至少检测一次脂蛋白(a)胆固醇。
核心结论
- LDLC是降脂治疗的主要靶标,治疗随访应使用相同方法测量或计算以 attenuate 方法间差异导致的治疗决策错误。
- 非HDLC应报告于所有标准血脂面板,并用于评估最佳降LDL治疗下的ASCVD残余风险,尤其对轻中度高甘油三酯血症(2-10 mmol/L)患者。
- 所有ASCVD风险患者应至少检测一次脂蛋白(a)胆固醇,尤其在LDLC对他汀治疗反应不佳者中。
研究设计与样本
- 欧洲动脉粥样硬化学会(EAS)与欧洲临床化学和实验室医学联盟(EFLM)联合共识小组发布的共识推荐。
主要发现
- 总胆固醇、甘油三酯、高密度脂蛋白胆固醇、LDLC及计算的非HDLC构成初级血脂面板,可在非空腹状态测量。
- 脂蛋白(a)胆固醇是测量或计算LDLC的一部分,应在所有ASCVD风险患者中至少评估一次。
- 额外检测载脂蛋白B(apoB)可发现仅基于LDLC常无法识别的LDL颗粒数量升高。
- 报告了欧洲20-100岁男性和女性的血脂、脂蛋白及载脂蛋白参考区间。
关键数值与推荐
- 轻中度高甘油三酯血症定义为2-10 mmol/L。
- 非HDLC计算为总胆固醇减去HDLC。
- 实验室应参考治疗决策阈值标注异常血脂值。
临床怎么用
- 使用非空腹状态可测量初级血脂面板(总胆固醇、甘油三酯、HDLC、LDLC、非HDLC)。
- 降脂治疗随访时,LDLC应使用与基线相同的方法测量或计算。
- 所有标准血脂面板应报告非HDLC,尤其轻中度高甘油三酯血症患者应评估非HDLC或apoB以评估残余风险。
- 所有ASCVD风险患者至少检测一次脂蛋白(a)胆固醇。
- 实验室应以治疗决策阈值标注异常血脂值,而非仅用参考区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently addressed present and future challenges in the laboratory diagnostics of atherogenic lipoproteins. Total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDLC), LDL cholesterol (LDLC), and calculated non-HDLC (=total - HDLC) constitute the primary lipid panel for estimating risk of atherosclerotic cardiovascular disease (ASCVD) and can be measured in the nonfasting state. LDLC is the primary target of lipid-lowering therapies. For on-treatment follow-up, LDLC shall be measured or calculated by the same method to attenuate errors in treatment decisions due to marked between-method variations. Lipoprotein(a) [Lp(a)]-cholesterol is part of measured or calculated LDLC and should be estimated at least once in all patients at risk of ASCVD, especially in those whose LDLC declines poorly upon statin treatment. Residual risk of ASCVD even under optimal LDL-lowering treatment should be also assessed by non-HDLC or apolipoprotein B (apoB), especially in patients with mild-to-moderate hypertriglyceridemia (2-10 mmol/L). Non-HDLC includes the assessment of remnant lipoprotein cholesterol and shall be reported in all standard lipid panels. Additional apoB measurement can detect elevated LDL particle (LDLP) numbers often unidentified on the basis of LDLC alone. Reference intervals of lipids, lipoproteins, and apolipoproteins are reported for European men and women aged 20-100 years. However, laboratories shall flag abnormal lipid values with reference to therapeutic decision thresholds.
引用
- Langlois MR, Nordestgaard BG, Langsted A, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med. 2020. PMID: 31855562. doi:10.1515/cclm-2019-1253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。